Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) – HC Wainwright issued their FY2028 earnings estimates for Plus Therapeutics in a research report issued to clients and investors on Friday, November 15th. HC Wainwright analyst S. Lee expects that the company will earn $0.28 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.00) per share.
Separately, Ascendiant Capital Markets reduced their price objective on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.
Plus Therapeutics Stock Up 1.7 %
Plus Therapeutics stock opened at $1.19 on Monday. Plus Therapeutics has a 52-week low of $1.15 and a 52-week high of $2.67. The firm has a market capitalization of $7.02 million, a price-to-earnings ratio of -0.47 and a beta of 0.69. The firm has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.66.
Institutional Investors Weigh In On Plus Therapeutics
An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC bought a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by institutional investors.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Recommended Stories
- Five stocks we like better than Plus Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What Are the U.K. Market Holidays? How to Invest and Trade
- Applied Materials Market Capitulates: Now is the Time to Buy
- What is the Nasdaq? Complete Overview with History
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
